11/3/2021

speaker
Conference Call Operator
Operator

Greetings and welcome to the Ametis' third quarter 2021 earnings conference call. At this time, all participants are on a listen-only mode. A question and answer session will follow the formal presentation. If you would like to ask a question, please press star 1 on your telephone keypad. If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Nick Moscato, Senior Vice President of Finance. Thank you. Please go ahead.

speaker
Unknown
Investor Relations Representative

Thank you, Operator, and welcome to the Emeticis Investor Conference call to discuss the results of the third quarter ended September 30th, 2021. A copy of our press release, supplemental slides, and related Form 8K filing with the SEC are available on the Investor Relations page of our website. Speaking on today's call from Emeticis will be Paul Cucero, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer, and Scott Ginn, Executive Vice President and Chief Financial Officer. Also joining us is Dave Kimmerle, Chief Legal and Government Affairs Officer. Before we get started with our call, I would like to remind everyone that statements made on this conference call today may constitute forward-looking statements and are protected under the safe harbor of the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to a Metasys today. The company assumes no obligation to update information provided on this call to reflect subsequent events other than as required under applicable securities laws. These forward-looking statements may involve a number of risks and uncertainties which may cause the company's results or actual outcomes to differ materially from such statements. These risks and uncertainties include factors detailed in our SEC filings, including our Forms 10-K, 10-Q, and 8-K. In addition, as required by SEC Regulation G, A reconciliation of any non-GAAP measures mentioned during our call today to the most comparable GAAP measures will also be available in our forms 10-K, 10-Q, and 8-K. Thank you, and now I'll turn the call over to Emeticis Chairman and CEO, Paul Cucero.

speaker
Paul Cucero
Chairman and Chief Executive Officer

Thanks, Nick, and welcome to the Emeticis 2021 Third Quarter Earnings Call. We have a lot to discuss on today's call. But before we dive in, I want to express my sincerest appreciation to all 21,000 plus Amedisys employees. Whether you are at a patient's bedside or supporting those providing the industry's best in class care, at Amedisys, we put quality before everything. And the unwavering dedication of our entire employee base has been delivering great patient care And this dedication to quality continues to be my greatest point of pride and largest source of inspiration. COVID-19 continues to change the dynamics of all of healthcare and how it is provided. Yet you all remain resolute in putting patients first and delivering industry leading metrics. For that, I thank you. Before I turn the call over to Chris and Scott, I'd like to say how proud and excited I am by our performance. This has been a tough if not brutal year. The incoming that's come at us we could not have imagined. I have a favorite quote from Teddy Roosevelt which best describes how we are dealing with the COVID era. Do what you can with what you have where you are. I've modified it a bit for us. Do the best you can with all you have. Hold strong and take ground. That's our motto. Amedisys did all that and more. A good company maximizes on what it can control. A great company responds to uncontrollable forces better than everyone else and, where possible, turns them into opportunities. For controllables, we built up our BD heads. We reduced our clinical turnover by 15%. We saw the labor issues in our industry and accelerated recruiting, increasing our hiring 40%. And we kept driving our quality ratings higher. 4.6 stars by our latest estimate. What we can't control is accelerated death rates due to COVID. Hospitals closing units due to labor shortages. Hospitals cutting electives to make room for COVID beds, nurses out on quarantine due to COVID, and clinicians choosing not to be vaccinated. In hospice, there's faster death rates due to COVID, which is affecting our ADC, but we're taking share and we're growing admissions. Our admissions are up when others are down. When ADC normalizes, which we're just starting to see signs of now, Our revenue will grow at rates we have typically seen. In home health, we lost visits due to quarantined clinicians and hospitals cutting back on electives. But we again gained share and managed to grow. These results are hard fought and hard won. We are a company that wins on controllables and pivots best on uncontrollables. Can we do better? We always try to. Have we made mistakes? Absolutely. But so far, it's been a remarkable year of performance in a tremendously turbulent time. Now, I'd like to discuss Contessa's performance during the quarter. Our newly formed high acuity care segment, or Contessa, experienced continued positive momentum in Q3. offering home-based recovery solutions for patients in need of acute-level care. Total admissions were 234 for the two months since the closing of the acquisition, an increase of 8.3% from our original forecast, pretty good for a company that joined us just two months ago. Demand for home-based acute services is extremely high across Contessa's existing joint venture markets and continues to grow. We are working with Contessa's leadership team to think through innovative ways to access more home nursing so that they can continue to capitalize and capture on this demand. The results so far are very promising as we have largely eliminated all of their vacancies. Contessa continued to demonstrate its ability to drive value to marquee health systems with the closing of its joint venture with the Henry Ford Health System. This partnership, which is expected to launch in Q4 21, will combine all three Contessa clinical models, including hospital at home, SNF at home, and palliative level care in the home. In addition to the Henry Ford partnership, David Wiltshire- contested just inked another substantial deal will be announcing in a week or so and is actively evaluating partnerships with 13 additional health systems. David Wiltshire- This will create an opportunity to more than double its footprint in terms of partnerships in operation we're way ahead of our growth goals for 2021 and 2022 which is very encouraging finally contested continues to add. payer sources, thus increasing our market's total addressable lives with the addition of the Medicare fee-for-service waiver in two markets, while also finalizing managed care contracts for the SNF and palliative clinical models in various markets. We are very pleased with the high acuity segment's performance, and we are excited by the new opportunities and capabilities Contessa brings to the table. mainly the ability to take care of sicker and more acutely ill patients in the home, the ability to provide this care taking full risk, and having the ability to incorporate and coordinate all this multiplicity of care across a single platform. We have doubled our addressable markets with Contessa's capabilities, and we can drive better profits for our hospital and payer partners in these arrangements, and deliver better outcomes and higher satisfaction to patients who want hospital and SNF-level care in the home at a lower cost. I'd like to thank and congratulate our Condesa partners on the great start. Before I turn it over to Chris, I'd like to note that as of the timing of the recording of our prepared remarks, the final 2022 home health reimbursement update has not been released. Though we do not expect much, if there is any deviation from the proposed rule, upon the final rule's release, we will analyze the emeticist-specific impact and update everyone accordingly. I'll now turn the call over to Chris to give us a rundown of our core business performance during the quarter. Chris?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-